on pipeline on our end Thank late-stage regarding discuss progress we extends made patients you, good Thank announcement touch through our the everyone. for the ocular this decision therapies. to focus treated of we us. are not wanted novel current conditions to that I runway Joshua, whose by strategy particular, In disease, cash morning Today XXXX. develop to that want have morning in joining made and a to our I for strategy you commercialize and the medicines being adequately
we more relevant the asset observed disease. more These R&D people clinical than of than of of in data and statistically the XX% lead conditions inflammatory conjunctivitis recent significant majority this population which anterior Day eye billion highlighted U.S. During our up disease, worldwide. dry make currently and in ocular affects allergic late-stage trials New in and reproxalap York X our clinically
and exacerbated economic drug global These The rising eye noted counts dry accelerate reproxalap ocular three to-date pollen development models by conjunctival effects pollution, allergy our expected during reproxalap to challenge field directly urbanization. for the has itching initiatives ocular of allergic relevant we an warming, clinical a clinically in conjunctivitis, as on into increasing burden during and of trends play study distinct trial patients demonstrated disease pilot R&D significant is trial, in clinical allergen and chamber allergy seasons. and Day a
has initiated clinical of X a INVIGORATE to ophthalmic reproxalap helped body INVIGORATE phase and of prior INVIGORATE ongoing XXX which will extensive be trial with phase evaluate XXXX subject again reported an trial. approximately This allergen compared controlled work trials chamber. subjects our AC to encompasses of the consistent XXX patients and solution randomized powered double efficacy itching safety in topical is inform nearly X X.XX% the to was primary which score. vehicle in crossover assess January the vehicle will masked INVIGORATE ocular endpoint
the in proceeding on we this and Patient expect INVIGORATE half from second enrollment is schedule of results year.
entrant this address the with to positioned an or adjunct growing We disease an are as we in first treatment opportunity lieu to believe in well novel in be we and uniquely corticosteroids. conjunctivitis of have either decades allergic antihistamines
development steps disease our noted RENEW Day eye regarding the trial symptom of X during RENEW in in both endpoint the of FDA thus our part control to phase meeting the trial formulation primary reproxalap met has path. X have of requested R&D a now we as X phase with Turning in dry our and next X part
plans update FDA second feedback of following expected in XXXX. an We on be future half dry the disease providing in development will eye
formulation time weeks score. dosing in fluorescein of statistically the presented we to patient data disease regimen the Day, Over dry both eye in At was R&D points ocular the assessed superior reproxalap were reported four staining investigator trials and where therapy and combining vehicle clinical same. three dryness
aforementioned head-to-head formulation formulation a of vision effects from the the of of ocular only a disease lower taste trial X clinical data trials observed X results Xiidra formulations a and presented patients Phase after blurry the Xiidra note recognized patients the RENEW hour trial novel retreated leading under positive therapy and current we for tolerability reproxalap of the reproxalap in compared we support in though treated tolerability is one which that also statistically believe over dry both discomfort, in both approved conditions. than eye and We as were disturbance Part versus reproxalap dosing symptomatic that
conjunctivitis XX has topical aggregate installation allergic no an is site of than ocular dry to and trials, event. date concerns, eye patients more been common reported with safety X,XXX disease studied adverse most Across irritation in mild transient observed and the reproxalap
support of the and key leaders potential an practicing of validation professionals. the there investigational believe no and We benefits stronger of healthcare opinion is product
So R&D was Paul a Day gratifying Kentucky as therapy ocular for first-line clinical of discussed renowned disease. internationally director Karpecki as hear Eye optometrist especially approved surface at the the Institute it to using reproxalap
currently our very in months. As the XX% work and condition Mass need R&D do or significant and treatment enrollment with Eye is dissatisfaction for PVR on unmet disease And of cause threatening the through therapy Dean the surface available retinopathy vitreous underway medical stay the our ADX-XXXX. in ADX-XXXX dry Phase who that of but Elliott patient Dr. trial noted ocular a three video patients detachment parallel highlights leading high beyond Ears sight failure a our of of among of is as the of perspectives Dr. retinal PVR, many website, recent proliferative X GUARD developed with A Karpecki prevention their not the surgery. on during level rare disease Day shown is current as
this expect We later year. on to the an GUARD progress provide update of
clinical to clinical development made our we've allergic conjunctivitis, we the in PVR. our on progress eye dry ocular to reproxalap ichthyosis to lymphoproliferative have Due prioritize disease for the ADX-XXXX the with on strategic disorder. ophthalmology and development for transplant near-term elected morning stage treatment associated of further dermal Syndrome hold this late all product place of post light of disease Sjögren treatment the and Larsson prioritization our pipeline initiatives topical we candidates In of decision of announced our
ophthalmic past at desire clinical strategic role. to lead on has important played pipeline comes role capacity. recently our want his global and during Clark to we Alcon appreciate Xiidra medical Dr. similar emphasis for and transitioning we roles development advancing Lomb. projects former most consulting years. vice Novartis. of Dr. that an consulting on is in I with served clinical XX Bausch renewed and was On at and Aldeyra with and global Aldeyra's Consistent senior announced senior ocular development an experience He officer stay behalf thank Gow as Takeda medical positions at for Shire to affairs have appointed and many four David disease his chief Dr. He a Gow on president company Dr. to that and Inotek, Clark years to our in we of in before as James development the Aldeyra the board a and the expert contributions
anti-inflammatory preclinical agreement collaborative with to of therapies our Janssen concluded prioritization. related activities, and consistent Research research new with has development Development our terms systemic In of
of the development of in inhibitor testing the continuing are expect disease to ADX-XXX, retinal treatment in an clinical and we investigational XXXX. for RASP be However,
we Phase testing administered disease X our ADX-XXX, RASPinhibitor is to planned been continue will of a the applicability of XXXX. the clinical a efforts, ocular this orally X trial advance is development be of focus also of novel While expected for the second diseases. primary completed. to The variety broad clinical Phase half believe immune-mediated we clinical near-term ADX-XXX year top line second data has plan in of to a quarter the initiation and has readout
in half EUDARIO moving information ADX-XXXX first enrollment phase year. forward investigator sponsored from completed be therapy the and this investigator inhibitor received was the trial expected trial PARP is of Based in Also patients. cancer with platinum to on of in X niraparib combination ovarian a patient in this the
Additional clinical mesothelioma contingent patients funding. is subsequent with work currently investigator on ADX-XXXX on
a and therapeutic Phase to disease number not our compelling ahead approaches adequately of clinical expected quarters in programs represent coming have addressed conjunctivitis, PVR conditions and serious eye the Looking address dry X allergic we by milestones treatments. current
outcomes We drugs patient that are to and that committed believe we achieve improve are well-positioned we developing to novel objective. that
Now to let over Joshua me the back for turn review. call financial his
